Freeline Therapeutics Holdings plc logo
Freeline Therapeutics Holdings plc FRLN
report update icon

Quarterly report 2023-Q3
added 05-23-2026

Freeline Therapeutics Holdings plc Market Cap | FRLN

As of September 25, 2026 Freeline Therapeutics Holdings plc has a market cap of $ 384 M


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap Freeline Therapeutics Holdings plc

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
261 M 44.3 M 255 M - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
261 M 44.3 M 187 M

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
AnaptysBio AnaptysBio
ANAB
1.59 B $ 51.7 1.83 % $ 1.5 B usaUSA
Allakos Allakos
ALLK
114 M - - $ 28.6 M usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
351 M $ 3.73 3.61 % $ 258 M britainBritain
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
125 M $ 1.89 0.53 % $ 107 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
262 M - -7.23 % $ 13 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
104 M - - $ 401 M usaUSA
Rezolute Rezolute
RZLT
409 M $ 3.94 1.87 % $ 299 M usaUSA
Evelo Biosciences Evelo Biosciences
EVLO
27 M - -14.46 % $ 27.9 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
5.65 B $ 2.52 1.17 % $ 6.21 B israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
11.7 B $ 61.35 0.06 % $ 11.8 B usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
562 M $ 9.64 0.46 % $ 449 M usaUSA
BioNTech SE BioNTech SE
BNTX
22 B $ 99.26 0.81 % $ 24 B germanyGermany
Genocea Biosciences Genocea Biosciences
GNCA
72.7 M - -15.0 % $ 3.04 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
2.78 B $ 3.63 3.93 % $ 795 M britainBritain
Amryt Pharma plc Amryt Pharma plc
AMYT
2.55 B - - $ 621 M britainBritain
G1 Therapeutics G1 Therapeutics
GTHX
173 M - - $ 370 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
4.81 M $ 2.17 0.46 % $ 3.57 M israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
999 M $ 14.24 0.35 % $ 1.27 B usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
234 M $ 3.03 0.3 % $ 251 M usaUSA
Codexis Codexis
CDXS
111 M $ 1.37 1.45 % $ 119 M usaUSA
Cerus Corporation Cerus Corporation
CERS
496 M $ 2.61 0.38 % $ 497 M usaUSA
AbbVie AbbVie
ABBV
400 B $ 265.12 0.09 % $ 469 B usaUSA
Humanigen Humanigen
HGEN
12.5 M - -81.12 % $ 4.28 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
226 M $ 1.17 1.48 % $ 137 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
962 M $ 12.65 2.76 % $ 3.78 B canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
252 M $ 5.43 2.65 % $ 288 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
2.04 B $ 31.48 1.16 % $ 2.09 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
4.64 M $ 4.12 1.98 % $ 50.3 M israelIsrael
Фармсинтез Фармсинтез
LIFE
2 B - - - russiaRussia
Cellectar Biosciences Cellectar Biosciences
CLRB
7.49 M $ 2.08 0.48 % $ 5.43 M usaUSA
IGM Biosciences IGM Biosciences
IGMS
84.7 M - - $ 76.9 M usaUSA
IMV IMV
IMV
6.84 M - - $ 13.1 M canadaCanada
Kinnate Biopharma Kinnate Biopharma
KNTE
124 M - - $ 123 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
52.7 M - - $ 231 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
11.8 B - - $ 12.2 B usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
11.4 M $ 1.15 1.67 % $ 13 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
4.11 B $ 84.95 0.13 % $ 7.99 B usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
1.4 B $ 22.64 0.85 % $ 717 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
3.75 B $ 118.51 4.93 % $ 12.3 B usaUSA
Chimerix Chimerix
CMRX
104 M - - $ 756 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
127 M $ 7.45 0.19 % $ 99.2 M usaUSA
Curis Curis
CRIS
9.48 M $ 0.88 0.85 % $ 11.6 M usaUSA
CorMedix CorMedix
CRMD
456 K $ 7.77 1.04 % $ 560 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
4.39 B $ 55.7 0.23 % $ 5.01 B schweizSchweiz
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
318 M $ 11.8 8.21 % $ 932 M usaUSA
Champions Oncology Champions Oncology
CSBR
83.8 M $ 4.95 0.38 % $ 68.5 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
847 M $ 4.88 0.62 % $ 935 M canadaCanada
Cue Biopharma Cue Biopharma
CUE
29.4 M $ 32.85 3.6 % $ 3.11 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
19.9 M $ 1.72 2.38 % $ 13.8 M usaUSA